Researchers at Cancer Research UK have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.
A hard-to-treat disease—mainly due to lack of early symptoms—pancreatic cancer accounts for 3% of cancers in the United States and about 7% of cancer deaths, according to the American Cancer Society. Now, researchers have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.
A clinical trial designed by Cancer Research UK will enroll patients with localized pancreatic cancer whose significant tumor burden eliminates surgery from the list of treatment options. Using chemoradiation, which is a combination of chemotherapy and radiotherapy, along with olaparib (a PARP inhibitor, currently approved for ovarian cancer by the FDA), the researchers hope to shrink the tumors to a size where surgery would once again be an option.
“This is the first time we’re looking at ways to make pancreatic cancer cells more sensitive to radiotherapy," Jeff Evans, chief investigator of the trial at the University of Glasgow, said in a statement. "One way to make pancreatic cancer a more treatable disease is to shrink the tumour enough to make surgery a possibility and we hope to see that happen in this trial."
The initial phase 1 study is small, with plans to recruit 36 patients, and will primarily be a dose-finding endeavor.
The trial design has a multi-pronged approach. Radiotherapy and a few chemotherapy agents cause DNA damage to cells, but cancer cells retain their ability to repair this damaged DNA and survive, which can lead to drug resistance. Olaparib, an inhibitor of PARP-1 (a protein that helps repair DNA damage), can stop this process and resensitize the cells to the DNA-damaging agents to cause cell death, resulting in tumor shrinkage.
Once the researchers have finalized on the best dose of olaparib, the second part of the trial will recruit patients who could possibly have surgery to demonstrate proof-of-concept.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More